{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:01:55Z","timestamp":1793394115759,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.heliyon.2023.e19222","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T04:40:56Z","timestamp":1694234456000},"page":"e19222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome"],"prefix":"10.1016","volume":"9","author":[{"given":"Xinyu","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5503-6663","authenticated-orcid":false,"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.heliyon.2023.e19222_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e19222_bib2","first-page":"123","article-title":"Crit rev oncol hematol. Immune dysregulation in myelodysplastic syndrome","volume":"122","author":"Wang","year":"2018","journal-title":"Clinical features, pathogenesis and therapeutic strategies"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib4","first-page":"180","volume":"14","author":"Jiang","year":"2021","journal-title":"Targeting CD47 for cancer immunotherapy"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib3","first-page":"69","article-title":"Proteins","volume":"47","author":"Mushegian","year":"2002","journal-title":"Refining structural and functional predictions for secretasome components by comparative sequence analysis"},{"issue":"16","key":"10.1016\/j.heliyon.2023.e19222_bib5","first-page":"3597","article-title":"Clin cancer res","volume":"21","author":"McCracken","year":"2015","journal-title":"Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 \"Don't Eat Me\" Signals"},{"issue":"17","key":"10.1016\/j.heliyon.2023.e19222_bib6","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib7","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1111\/ajco.13566","article-title":"Phagocytosis checkpoints on hematopoietic stem cells in patients with myelodysplastic syndromes","volume":"18","author":"Dong","year":"2022","journal-title":"Asia pac J clin oncol"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e19222_bib8","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19222_bib9","article-title":"Best pract res clin haematol","volume":"33","author":"Swoboda","year":"2020","journal-title":"The promise of macrophage directed checkpoint inhibitors in myeloid malignancies"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MOH.0000000000000691","article-title":"The cluster of differentiation 47\/signal-regulatory protein alpha axis in myeloid malignancies","volume":"29","author":"Wang","year":"2022","journal-title":"Curr Opin Hematol. Targeting"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e19222_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann hematol"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19222_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","article-title":"The past and future of CD33 as therapeutic target in acute myeloid leukemia","volume":"28","author":"Laszlo","year":"2014","journal-title":"Blood rev"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e19222_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e19222_bib13","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1172\/JCI67580","article-title":"Induction of myelodysplasia by myeloid-derived suppressor cells","volume":"123","author":"Chen","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.heliyon.2023.e19222_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1749-6632.2011.06449.x","article-title":"CD33-related siglecs as potential modulators of inflammatory responses","volume":"1253","author":"Crocker","year":"2012","journal-title":"Ann N Y acad sci"},{"issue":"16","key":"10.1016\/j.heliyon.2023.e19222_bib15","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1128\/MCB.00383-07","article-title":"Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity","volume":"27","author":"Tateno","year":"2007","journal-title":"Mol cell biol"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19222_bib16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U","article-title":"Differences in CD33 intensity between various myeloid neoplasms","volume":"118","author":"Jilani","year":"2002","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.heliyon.2023.e19222_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.leukres.2018.07.009","article-title":"Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells","volume":"71","author":"Ogata","year":"2018","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19222_bib18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.exphem.2010.03.016","article-title":"Circulating CD33 and its clinical value in acute leukemia","volume":"38","author":"Abdool","year":"2010","journal-title":"Exp hematol"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19222_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e19222_bib21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat rev immunol"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19222_bib22","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.ymthe.2022.02.005","article-title":"Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex vivo in MDS and melanoma","volume":"30","author":"Cheng","year":"2022","journal-title":"Mol Ther"},{"issue":"6917","key":"10.1016\/j.heliyon.2023.e19222_bib23","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.heliyon.2023.e19222_bib24","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","article-title":"CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets","volume":"123","author":"Gleason","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e19222_bib25","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00018-015-1866-6","article-title":"Regulation and function of the NFE2 transcription factor in hematopoietic and non-hematopoietic cells","volume":"72","author":"Gasiorek","year":"2015","journal-title":"Cell mol life sci"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.bbadis.2016.11.005","article-title":"Nrf2 signaling pathway: Pivotal roles in inflammation","volume":"1863","author":"Ahmed","year":"2017","journal-title":"Biochim biophys acta mol basis dis"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib32","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jss.2010.05.058","article-title":"Correlation of Nrf2, HO-1, and MRP3 in gallbladder cancer and their relationships to clinicopathologic features and survival","volume":"164","author":"Wang","year":"2010","journal-title":"Y. J Surg Res"},{"key":"10.1016\/j.heliyon.2023.e19222_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11624","article-title":"Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription","volume":"7","author":"Kobayashi","year":"2016","journal-title":"Nat commun"},{"key":"10.1016\/j.heliyon.2023.e19222_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/srep00201","article-title":"Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis","volume":"1","author":"Pareek","year":"2011","journal-title":"Sci rep"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41419-020-03331-x","article-title":"Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting Inside MS","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.heliyon.2023.e19222_bib30","first-page":"2893","article-title":"Correlation between nuclear factor E2-related factor 2 expression and gastric cancer progression","volume":"21","author":"Zheng","year":"2015","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e19222_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158705","article-title":"FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1\/NRF2 signaling pathway","volume":"133","author":"Zhou","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2141.2005.05416.x","article-title":"Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2","volume":"129","author":"Goerttler","year":"2005","journal-title":"Br J haematol"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2009-11-254664","article-title":"AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2","volume":"116","author":"Wang","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.heliyon.2023.e19222_bib35","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1073\/pnas.1002890107","article-title":"Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia","volume":"107","author":"Wu","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e19222_bib36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3324\/haematol.2018.197749","article-title":"The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes","volume":"104","author":"Lin","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41416-021-01570-z","article-title":"Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing","volume":"126","author":"Jiang","year":"2022","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19222_bib38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41397-020-0154-5","article-title":"Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients","volume":"20","author":"S\u00e1nchez","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19222_bib39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1471-4906(02)02223-8","article-title":"CD200 and membrane protein interactions in the control of myeloid cells","volume":"23","author":"Barclay","year":"2002","journal-title":"Trends immunol"},{"key":"10.1016\/j.heliyon.2023.e19222_bib40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neuroscience.2018.10.030","article-title":"Role of the CD200-CD200R Axis During Homeostasis and Neuroinflammation","volume":"405","author":"Manich","year":"2019","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19222_bib41","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.3390\/ijms22041602","article-title":"CD200:CD200R Interactions and Their Importance in Immunoregulation","volume":"22","author":"Kotwica-Mojzych","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.heliyon.2023.e19222_bib42","article-title":"CD200 and chronic lymphocytic leukemia","volume":"10","author":"D'Arena","year":"2020","journal-title":"Biological and Clinical Relevance. Front Oncol"},{"key":"10.1016\/j.heliyon.2023.e19222_bib43","article-title":"CD200 and chronic lymphocytic leukemia: Biological and Clinical Relevance","volume":"10","author":"D'Arena","year":"2020","journal-title":"Front oncol"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib44","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4049\/jimmunol.162.2.774","article-title":"Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells","volume":"162","author":"Gorczynski","year":"1999","journal-title":"J Immunol"},{"issue":"13","key":"10.1016\/j.heliyon.2023.e19222_bib45","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Moreaux","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e19222_bib46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.leu.2404559","article-title":"CD200 as a prognostic factor in acute myeloid leukaemia","volume":"21","author":"Tonks","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbrc.2007.11.103","article-title":"CD200: a putative therapeutic target in cancer","volume":"366","author":"Moreaux","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e19222_bib48","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1111\/jcmm.16458","article-title":"Ferroptosis-related gene CHAC1 is a valid indicator for the poor prognosis of kidney renal clear cell carcinoma","volume":"25","author":"Li","year":"2021","journal-title":"J. Cell Mol. Med."},{"issue":"21","key":"10.1016\/j.heliyon.2023.e19222_bib49","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1182\/bloodadvances.2020001802","article-title":"CD200 expression marks leukemia stem cells in human AML","volume":"4","author":"Ho","year":"2020","journal-title":"Blood adv"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e19222_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002968","article-title":"Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML","volume":"9","author":"Herbrich","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e19222_bib51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.31557\/APJCP.2020.21.3.743","article-title":"Clinical Significance of CD200 and CD56 expression in patients with acute myeloid leukemia","volume":"21","author":"Aref","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.heliyon.2023.e19222_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2017.01.021","article-title":"Over-expression of CD200 predicts poor prognosis in MDS","volume":"56","author":"Chen","year":"2017","journal-title":"Leuk res"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib53","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s40425-019-0710-1","article-title":"Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200","volume":"7","author":"Mahadevan","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjh.17125","article-title":"Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo","volume":"193","author":"Rastogi","year":"2021","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.heliyon.2023.e19222_bib55","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/bloodadvances.2020003534","article-title":"Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy","volume":"5","author":"Diamanti","year":"2021","journal-title":"Blood adv"},{"issue":"24","key":"10.1016\/j.heliyon.2023.e19222_bib56","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1158\/0008-5472.CAN-04-2682","article-title":"Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction","volume":"64","author":"Castriconi","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.heliyon.2023.e19222_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3948928","article-title":"Overexpression of an immune checkpoint (CD155) in breast cancer associated with prognostic significance and exhausted tumor-infiltrating lymphocytes: A Cohort Study","volume":"2020","author":"Li","year":"2020","journal-title":"J immunol res"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e19222_bib58","doi-asserted-by":"crossref","first-page":"882","DOI":"10.18632\/oncotarget.594","article-title":"Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma","volume":"3","author":"Bevelacqua","year":"2012","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib59","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-020-00913-2","article-title":"CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma","volume":"13","author":"Lupo","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19222_bib60","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3892\/ol.2013.1280","article-title":"Prognostic significance of CD155 mRNA expression in soft tissue sarcomas","volume":"5","author":"Atsumi","year":"2013","journal-title":"Oncol lett"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e19222_bib61","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/eji.201545480","article-title":"TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals","volume":"45","author":"Wang","year":"2015","journal-title":"Eur J immunol"},{"issue":"24","key":"10.1016\/j.heliyon.2023.e19222_bib62","doi-asserted-by":"crossref","first-page":"9180","DOI":"10.1158\/0008-5472.CAN-04-2682","article-title":"Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction","volume":"64","author":"Castriconi","year":"2004","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e19222_bib63","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.4049\/jimmunol.172.7.3994","article-title":"Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)","volume":"172","author":"Fuchs","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.heliyon.2023.e19222_bib64","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3389\/fonc.2020.01595","article-title":"Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes","volume":"10","author":"Meng","year":"2020","journal-title":"Front oncol"},{"issue":"19","key":"10.1016\/j.heliyon.2023.e19222_bib65","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/0008-5472.CAN-16-0839","article-title":"Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells","volume":"76","author":"Sarhan","year":"2016","journal-title":"Cancer res"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97400-6","article-title":"DNAM-1\/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis","volume":"11","author":"Chashchina","year":"2021","journal-title":"Sci rep"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19222_bib67","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/cancers11060877","article-title":"DNAM-1 and the TIGIT\/PVRIG\/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy","volume":"11","author":"Sanchez-Correa","year":"2019","journal-title":"Cancers (basel)"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3892\/ol.2021.13169","article-title":"CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia","volume":"23","author":"Kaito","year":"2022","journal-title":"Oncol lett"},{"key":"10.1016\/j.heliyon.2023.e19222_bib69","article-title":"Identify the prognostic and immune profile of VSIR in the tumor microenvironment: a pan-cancer analysis","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19222_bib70","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1002\/cam4.5409","article-title":"Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes","volume":"12","author":"Yao","year":"2023","journal-title":"Cancer med"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib81","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib71","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-065X.2009.00774.x","article-title":"Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology","volume":"229","author":"Nolte","year":"2009","journal-title":"Immunol rev"},{"key":"10.1016\/j.heliyon.2023.e19222_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","article-title":"CD70: An emerging target in cancer immunotherapy","volume":"155","author":"Jacobs","year":"2015","journal-title":"Pharmacol ther"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19222_bib73","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/smim.1998.0154","article-title":"Control of lymphocyte function through CD27-CD70 interactions","volume":"10","author":"Lens","year":"1998","journal-title":"Semin. Immunol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19222_bib78","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.4049\/jimmunol.1300868","article-title":"CD70 is downregulated by interaction with CD27","volume":"191","author":"Kuka","year":"2013","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19222_bib79","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.4049\/jimmunol.152.4.1762","article-title":"Characterization of the human CD27 ligand, a novel member of the TNF gene family","volume":"152","author":"Hintzen","year":"1994","journal-title":"J immunol"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib80","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.imlet.2011.01.008","article-title":"Function of CD27 in helper T cell differentiation","volume":"136","author":"Libregts","year":"2011","journal-title":"Immunol Lett"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e19222_bib74","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/ijc.29637","article-title":"Soluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts","volume":"137","author":"Bassig","year":"2015","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e19222_bib75","first-page":"1394","article-title":"Hum Pathol. CD70 expression patterns in renal cell carcinoma","volume":"43","author":"Jilaveanu","year":"2012","journal-title":"Camp RL"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19222_bib76","first-page":"1152","article-title":"Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells","volume":"147","author":"Agathanggelou","year":"1995","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e19222_bib77","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7150\/jca.10360","article-title":"CD70: A Potential Target in Breast Cancer?","volume":"5","author":"Petrau","year":"2014","journal-title":"J Cancer"},{"issue":"49","key":"10.1016\/j.heliyon.2023.e19222_bib91","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1710877114","article-title":"Anti-SIRP\u03b1 antibody immunotherapy enhances neutrophil and macrophage antitumor activity","volume":"114","author":"Ring","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib82","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI45977","article-title":"CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression","volume":"122","author":"Sch\u00fcrch","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib83","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000070661","article-title":"Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma","volume":"24","author":"Kok","year":"2003","journal-title":"Tumour biol"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e19222_bib84","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaci.2015.02.022","article-title":"Novel mutations in TNFRSF7\/CD27: clinical, immunologic, and genetic characterization of human CD27 deficiency","volume":"136","author":"Alkhairy","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib85","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1365-2141.2003.04260.x","article-title":"CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease","volume":"121","author":"Guikema","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.heliyon.2023.e19222_bib86","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcmd.2019.03.009","article-title":"Increased CD8+CD27+perforin+ T cells and decreased CD8+CD70+ T cells may be immune biomarkers for aplastic anemia severity","volume":"77","author":"Zhao","year":"2019","journal-title":"Blood cells mol dis"},{"issue":"18","key":"10.1016\/j.heliyon.2023.e19222_bib87","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2016.70.1508","article-title":"Safety and activity of Varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors","volume":"35","author":"Burris","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 3","key":"10.1016\/j.heliyon.2023.e19222_bib88","article-title":"New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)","volume":"4","author":"Starzer","year":"2020","journal-title":"ESMO Open"},{"issue":"43","key":"10.1016\/j.heliyon.2023.e19222_bib89","doi-asserted-by":"crossref","first-page":"74058","DOI":"10.18632\/oncotarget.18202","article-title":"Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy","volume":"8","author":"Jacobs","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2023.e19222_bib90","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/OTT.S44445","article-title":"Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas","volume":"6","author":"Liu","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib92","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00280-017-3508-1","article-title":"B7-H3 in tumors: friend or foe for tumor immunity?","volume":"81","author":"Li","year":"2018","journal-title":"Cancer chemother pharmacol"},{"key":"10.1016\/j.heliyon.2023.e19222_bib93","article-title":"B7-H3\/CD276: An Emerging Cancer Immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e19222_bib94","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/85339","article-title":"B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat immunol"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e19222_bib95","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ni967","article-title":"The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses","volume":"4","author":"Suh","year":"2003","journal-title":"Nat immunol"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19222_bib96","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","article-title":"Murine B7-H3 is a negative regulator of T cells","volume":"173","author":"Prasad","year":"2004","journal-title":"J immunol"},{"issue":"34","key":"10.1016\/j.heliyon.2023.e19222_bib97","doi-asserted-by":"crossref","first-page":"12640","DOI":"10.1073\/pnas.0405025101","article-title":"Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis","volume":"101","author":"Castriconi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e19222_bib98","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains","volume":"172","author":"Steinberger","year":"2004","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib99","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12894-021-00829-0","article-title":"Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma","volume":"21","author":"Aicher","year":"2021","journal-title":"BMC Urol"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e19222_bib100","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201054","article-title":"Prognostic value of immune checkpoint molecules in breast cancer","volume":"40","author":"Fang","year":"2020","journal-title":"Biosci rep"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib101","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41419-020-2252-3","article-title":"B7-H3 promotes colorectal cancer angiogenesis through activating the NF-\u03baB pathway to induce VEGFA expression","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis"},{"issue":"21","key":"10.1016\/j.heliyon.2023.e19222_bib102","doi-asserted-by":"crossref","first-page":"7831","DOI":"10.1002\/cam4.4284","article-title":"Integrated analysis reveals distinct molecular, clinical, and immunological features of B7-H3 in acute myeloid leukemia","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib103","doi-asserted-by":"crossref","first-page":"11987","DOI":"10.1080\/21655979.2021.2001182","article-title":"Expression characteristic of 4Ig B7-H3 and 2Ig B7-H3 in acute myeloid leukemia","volume":"12","author":"Zhang","year":"2021","journal-title":"Bioengineered"},{"issue":"14","key":"10.1016\/j.heliyon.2023.e19222_bib104","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin cancer res"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e19222_bib105","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","article-title":"Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia","volume":"27","author":"Lichtman","year":"2021","journal-title":"Clin cancer res"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19222_bib106","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol Med"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19222_bib107","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/ijc.31112","article-title":"Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT\/GSK-3\u03b2\/\u03b2-catenin\/cyclinD1 signaling pathway","volume":"142","author":"Yu","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.heliyon.2023.e19222_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/260983","article-title":"CD73 is critical for the resolution of murine colonic inflammation","volume":"2012","author":"Bynoe","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e19222_bib109","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2217\/imt-2018-0200","article-title":"CD73: an emerging checkpoint for cancer immunotherapy","volume":"11","author":"Chen","year":"2019","journal-title":"Immunotherapy"},{"issue":"15","key":"10.1016\/j.heliyon.2023.e19222_bib110","doi-asserted-by":"crossref","first-page":"8674","DOI":"10.1111\/jcmm.15500","article-title":"CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer","volume":"24","author":"Chen","year":"2020","journal-title":"J. Cell Mol. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e19222_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw4304","article-title":"Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML","volume":"5","author":"Jakobsen","year":"2019","journal-title":"Sci adv"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib112","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-019-0728-3","article-title":"Downregulation of CD73 associates with T cell exhaustion in AML patients","volume":"12","author":"Kong","year":"2019","journal-title":"J hematol oncol"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib113","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1930391","article-title":"Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML","volume":"10","author":"Brauneck","year":"2021","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e19222_bib114","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking Antibodies Targeting the CD39\/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell rep"},{"key":"10.1016\/j.heliyon.2023.e19222_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.613204","article-title":"CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High Therapeutic Potential","volume":"11","author":"Konduri","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.heliyon.2023.e19222_bib116","article-title":"A pan-cancer analysis of CD161, a Potential New Immune Checkpoint","volume":"12","author":"Zhou","year":"2021","journal-title":"Front immunol"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e19222_bib117","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood-2016-05-713347","article-title":"A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML","volume":"129","author":"Alsuliman","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib118","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.leukres.2004.06.005","article-title":"The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy","volume":"29","author":"Yoneda","year":"2005","journal-title":"Leuk res"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e19222_bib119","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood.2022015522","article-title":"Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse","volume":"140","author":"Gournay","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e19222_bib120","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","article-title":"Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis","volume":"184","author":"Mathewson","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib121","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","article-title":"Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma","volume":"184","author":"Sun","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2023.e19222_bib122","article-title":"Human ILC1s Target Leukemia Stem Cells and Control Development of AML","author":"Caligiuri","year":"2023","journal-title":"Res Sq [Preprint]"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e19222_bib123","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/cancers14102560","article-title":"Glutathione Peroxidase GPX1 and Its Dichotomous Roles in Cancer","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers (basel)"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166268","article-title":"GPX1-associated prognostic signature predicts poor survival in patients with acute myeloid leukemia and involves in immunosuppression","volume":"1868","author":"Zhang","year":"2022","journal-title":"Biochim biophys acta mol basis dis"},{"key":"10.1016\/j.heliyon.2023.e19222_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2021.104296","article-title":"MiR-185-5p suppresses acute myeloid leukemia by inhibiting GPX1","volume":"140","author":"Pang","year":"2022","journal-title":"Microvasc res"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e19222_bib126","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1158\/2326-6066.CIR-18-0489","article-title":"Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression","volume":"7","author":"Xu","year":"2019","journal-title":"Cancer immunol res"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e19222_bib127","article-title":"Oncoimmunology","volume":"7","author":"Wang","year":"2018","journal-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-023-01410-y","article-title":"STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia","volume":"16","author":"Mo","year":"2023","journal-title":"J Hematol Oncol. Targeting"},{"key":"10.1016\/j.heliyon.2023.e19222_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.580557","article-title":"Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity","volume":"11","author":"Yasinska","year":"2020","journal-title":"Front immunol"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e19222_bib130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-023-01410-y","article-title":"STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia","volume":"16","author":"Mo","year":"2023","journal-title":"J Hematol Oncol. Targeting"},{"key":"10.1016\/j.heliyon.2023.e19222_bib131","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2017.01.001","article-title":"Second- and third-generation drugs for immuno-oncology treatment-The more the better?","volume":"74","author":"Dempke","year":"2017","journal-title":"Eur J cancer"},{"issue":"6828","key":"10.1016\/j.heliyon.2023.e19222_bib132","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/35069112","article-title":"Structural basis for co-stimulation by the human CTLA-4\/B7-2 complex","volume":"410","author":"Schwartz","year":"2001","journal-title":"Nature"},{"issue":"6828","key":"10.1016\/j.heliyon.2023.e19222_bib133","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/35069118","article-title":"Crystal structure of the B7-1\/CTLA-4 complex that inhibits human immune responses","volume":"410","author":"Stamper","year":"2001","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib134","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1074-7613(02)00362-X","article-title":"The interaction properties of costimulatory molecules revisited","volume":"17","author":"Collins","year":"2002","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e19222_bib135","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1517\/14712598.2015.1051028","article-title":"Programmed death-1 checkpoint blockade in acute myeloid leukemia","volume":"15","author":"Sehgal","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"5899","key":"10.1016\/j.heliyon.2023.e19222_bib136","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e19222_bib137","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib138","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/ajco.13236","article-title":"Higher frequency of the CTLA-4+ LAG-3+ T-cell subset in patients with newly diagnosed acute myeloid leukemia","volume":"16","author":"Chen","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e19222_bib139","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.31557\/APJCP.2020.21.8.2225","article-title":"Prognostic Value of CD200 Expression and Soluble CTLA-4 Concentrations in Intermediate and High-Risk Myelodysplastic Syndrome Patients","volume":"21","author":"Aref","year":"2020","journal-title":"Asian pac J cancer prev"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e19222_bib140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for Patients with Relapse after Allogeneic Transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"issue":"6716","key":"10.1016\/j.heliyon.2023.e19222_bib141","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/16717","article-title":"ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28","volume":"397","author":"Hutloff","year":"1999","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e19222_bib142","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17474086.2020.1819233","article-title":"Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?","volume":"13","author":"Bewersdorf","year":"2020","journal-title":"Expert Rev Hematol"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023064307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023064307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:18:23Z","timestamp":1784927903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023064307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":142,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2405844023064307"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19222","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e19222"}}